Insights Blog
Explore our thought leadership insights, as life science technologies evolve and accelerate.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
DeciBio Q&A
Pharma & Biotech
ADCs, Texas, and CrossBridge Bio: A Discussion with Dr. Michael Torres, CEO of CrossBridge Bio
Dr. Torres sheds light on the dynamic growth of Texas' life sciences ecosystem, underscoring statewide efforts and philanthropy initiatives driving unprecedented support for innovative enterprises.
July 12, 2024
DeciBio Q&A
Pharma & Biotech
ADCs, Texas, and CrossBridge Bio: A Discussion with Dr. Michael Torres, CEO of CrossBridge Bio
Dr. Torres sheds light on the dynamic growth of Texas' life sciences ecosystem, underscoring statewide efforts and philanthropy initiatives driving unprecedented support for innovative enterprises.
July 12, 2024
adjuvant cell therapy
Cell & Gene Tx
Infographic
Clinical Diagnostics
DeciBio NGS DxBook - Sample Prep Vendors
Some additional insights from our latest NGS DxBook report, this time focusing on the competitive landscape of sample prep vendors in the clinical oncology.
July 1, 2024
Infographic
Clinical Diagnostics
DeciBio NGS DxBook - Sample Prep Vendors
Some additional insights from our latest NGS DxBook report, this time focusing on the competitive landscape of sample prep vendors in the clinical oncology.
July 1, 2024
DeciBio News
DxBooks Data Insights
.png)
Newsletter Update
Pharma & Biotech
Next-Generation Therapeutics Newsletter | June Roundup 2024
Read about the latest updates in the Next-Generation Therapeutics space in the month of June.
July 1, 2024
Newsletter Update
Pharma & Biotech
Next-Generation Therapeutics Newsletter | June Roundup 2024
Read about the latest updates in the Next-Generation Therapeutics space in the month of June.
July 1, 2024
Next-Generation Therapeutics
DeciBio Q&A
Pharma & Biotech
Exploring AAV as a Therapeutic Modality: Insights from Paul Wille, Director of Product Development at Abeona Therapeutics
We recently sat down with Paul Wille, Director of Product Development at Abeona Therapeutics. He reviews his take on AAV as a modality and the field as a whole.
June 24, 2024
DeciBio Q&A
Pharma & Biotech
Exploring AAV as a Therapeutic Modality: Insights from Paul Wille, Director of Product Development at Abeona Therapeutics
We recently sat down with Paul Wille, Director of Product Development at Abeona Therapeutics. He reviews his take on AAV as a modality and the field as a whole.
June 24, 2024
Cell & Gene Tx
DeciBio Q&A
Pharma & Biotech
Revolutionizing ADCs: A Q&A with BioLoomics Founder Doug Chapnick on Innovation and New CSO Appointment
Dr. Doug Chapnick, CEO of BioLoomics, discusses their mission to improve antibody-drug conjugates (ADCs) for cancer treatment, their technology validation efforts, AI exploration, and the hiring of new CSO Kurt Gish.
June 13, 2024
DeciBio Q&A
Pharma & Biotech
Revolutionizing ADCs: A Q&A with BioLoomics Founder Doug Chapnick on Innovation and New CSO Appointment
Dr. Doug Chapnick, CEO of BioLoomics, discusses their mission to improve antibody-drug conjugates (ADCs) for cancer treatment, their technology validation efforts, AI exploration, and the hiring of new CSO Kurt Gish.
June 13, 2024
adjuvant cell therapy
Newsletter Update
Clinical Diagnostics
Liquid Biopsy | May Roundup 2024
May was a productive month for Liquid Biopsy (LBx). In particular, there were a number of notable clinical and regulatory updates.
June 11, 2024
Newsletter Update
Clinical Diagnostics
Liquid Biopsy | May Roundup 2024
May was a productive month for Liquid Biopsy (LBx). In particular, there were a number of notable clinical and regulatory updates.
June 11, 2024
Liquid Biopsy
Precision Medicine is evolving at a rapid pace
Discover how we can help
Get in Touch
© DeciBio 2023 | All rights reserved